Tuesday, November 4, 2014

Dr. Xuejun Parsons, the founder of Xcelthera Inc and San Diego Regenerative Medicine Institute, is invited to speak at GTCBio XY Congress – Female and Male Cancer Research & Drug Discovery in San Diego, CA

Presentation Title: Embedding lineage-specific programs into the open epigenomic landscape of pluripotent human embryonic stem cells offers a new repository of human stem cell therapy derivatives for regenerative medicine.

Abstract: The intrinsic ability of a pluripotent human embryonic stem cell (hESC) for both unlimited self-renewal and unrestricted differentiation into clinically-relevant lineages makes it a practically inexhaustible source of replacement cells for human tissue and function restoration. Therefore, it has been regarded as an ideal source to provide a large supply of functional human cells to heal the damaged or lost tissues that have naturally limited capacity for renewal, such as the human heart and brain. Recent technology breakthroughs enable direct conversion of pluripotent hESCs by small molecule induction into a large supply of lineage-specific neuronal cells or heart muscle cells. The openness of pluripotent epigenome differentiates the active pluripotency of normal hESCs from the repressive pluripotency of abnormal reprogrammed cells and cancer cells. Nuclear translocation of NAD-dependent histone deacetylase SIRT1 and global chromatin silencing lead to hESC cardiac fate determination, while silencing of pluripotence-associated hsa-miR-302 family and drastic up-regulation of neuroectodermal Hox miRNA hsa-miR-10 family lead to hESC neural fate determination. Such advancements have demonstrated the direct pharmacologic utility and capacity of hESC therapy derivatives for human CNS and myocardium regeneration and, thus, have presented the hESC therapy derivatives as a powerful pharmacologic agent of cellular entity for CNS and heart repair. Transforming non-functional pluripotent hESCs into fate-restricted functional human cell therapy derivatives dramatically increases the clinical efficacy of graft-dependent repair and safety of hESC-derived cellular products, marking a turning point in cell-based regenerative medicine from current studies in animals towards human trials.

Time and Location: Thursday, Nov. 6, 2014 at Mission Ballroom III, Hyatt Regency Mission Bay San Diego, 1441 Quivira Rd, San Diego, CA 92109


Biomed Realty Trust Inc, a Public Company that has Failed to Disclose its Legal Proceedings to SEC and the Public against SEC Regulations and Public Policy, Uses Fraudulent Lease, Faulty Verdict, Malicious Prosecution, Extortionate Demand, Legal Threat, SLAPP Lawsuit to Harass, Intimidate, Censor, Damage, and Patent Troll Private Human Embryonic Stem Cell Startup and Voice of Regenerative Medicine Blog for Financial Conflict of Interest against California Civil Code Procedure and Public Policy

All the information disclosed below is privileged and provided by BMR, SDRMI, and other sources through case discovery. This blog makes no representations as to accuracy, completeness, correctness, reliability, suitability, or validity of this information. The content on this blog is the opinion only, not intended to malign any religion, ethnic group, club, organization, company, or individual, or anyone or anything.

BioMed Realty Trust Inc (BMR) -- Biomed Realty Trust Inc, Biomed Realty LP, BMR-Bunker Hill LP -- is the largest public-traded commercial real estate specializing leasing laboratory spaces for life science industry. BMR has failed to disclose its legal proceedings to the United States Security and Exchange Commission (SEC) and the Public in consecutive quarterly reports against SEC regulations and Public Policy (please see http://www.sec.gov/ ). BMR’s board members include trustees and president of Salk Institute; trustee of Stanford University; CEO of Amylin Pharmaceuticals; boards of directors of Illumina, Geron Corporation, Alliance Pharmaceutical Corp, Corcept Therapeutics, and Castle Biosciences; the advisory councils of the University of California San Diego and the University of Miami; President of Roth Capital (please see http://www.biomed.com  ). BMR’s biotechnology company investment portfolio includes some of the trailblazers in human embryonic stem cell lines, such as Geron and Asterias Biotherapeutics, a subsidiary of Biotime, which dosed on stem cell assets of Geron in October 2013 under a ~ $40 million deal for acquiring four cell lines, including OPC1, that were shelved by Geron. Asterias entered into an 8-year lease contract with BMR in January 2014 that worth ~$1.5 million/year, and subsequently, received a $14.3 million award from California Institute for Regenerative Medicine (CIRM) in May 2014 to continue clinical trial of OPC1 for spinal cord injury abandoned by Geron in November 2011. Those public developments indicate that BMR, a real estate company, has millions of money tangle with California stem cell agency and possibly other powerful systems. Therefore, although a large and powerful public company in commercial real estate, BMR indeed has real financial conflict of interest with private stem cell startup in life sciences industry and has been using the legal systems for their improper purposes by waging a legal war on San Diego Regenerative Medicine Institute (SDRMI), a non-profit 501c3 tax-exempt human embryonic stem cell research start-up in life science industry that, BMR know, cannot be burden with the costs of legal defenses and any legal counsels. BMR has been using fraudulent lease, faulty verdict, malicious prosecution, extortionate demand, legal threat, SLAPP lawsuit to harass, intimidate, censor, damage, and patent troll private human embryonic stem cell startup and Voice of Regenerative Medicine, a human embryonic stem cell blog, against California Civil Code Procedure and Public Policy for their malicious intention and despicable conduct to take control of SDRMI’s human embryonic stem cell assets and patent, liquidate SDRMI assets, drive SDRMI to bankruptcy, and destroy private stem cell startup in the life science industry that BMR has real financial conflict of interest with (please see image files of BMR extortionate demand letters for SDRMI stem cell patent provided by BMR themselves below).

BMR, a public-traded company, has been a party of multiple legal proceedings including case#37-2014-00034661, case#37-2013-00038680, and case#37-2012-00042147 (court records can be viewed at http://www.sdcourt.ca.gov), which disclosed through case discoveries BMR’s shocking malicious intention and despicable conducts in illegal confiscation and destruction of valuable human embryonic stem cell lines and stem cell research materials of SDRMI – a privately-hold stem cell startup in life science industry, and illegal confiscation and sell of stem cell research equipment of SDRMI with its partner organizations through fraudulent lease against public policy, invalid legal documents, false statements in legal documents under the penalty of perjury under the laws of the State of California, default and judgment that contain multiple legal deficiencies, and failure to follow proper legal procedures (please see image files provided by BMR themselves below). However, BMR has reported to SEC repeatedly during last consecutive quarters that BMR is not currently a party to any legal proceedings nor is any legal proceeding threatened against BMR that BMR believe would have a material adverse effect on its financial position, results of operations or liquidity against SEC regulations (please see http://www.sec.gov/). To cover up that BMR has violated public policy and government regulations to deliberately withhold information about its legal proceedings and multiple legal deficiencies to SEC and the Public, BMR is making false accusations and alleging defamation lawsuit (Case#37-2014-00034661, court records can be viewed at http://www.sdcourt.ca.gov), threatening restraining order and injunctions to bully Voice of Regenerative Medicine – a human embryonic stem cell research blog – and extort private sector unrelated individuals and startups for speaking truth about BMR’s legal proceedings that contain multiple legal deficiencies; violates the legal rights, ownership, and privacy of US private organizations and citizens, including US veteran and POW, entitled by law; and resulted in deliberate destruction to human embryonic stem cells of SDRMI and devastating damages to private life science startup (case#37-2013-00038680, case#37-2012-00042147, and case#37-2014-00034661, court records can be viewed at http://www.sdcourt.ca.gov, please see image files and BMR attorney’s frequent ex parte contacts and extortionate demand letters provided by BMR themselves below). What BMR, a public company that has failed to disclose its legal proceedings to SEC against public policy and government regulations, has to hide?

In May 2014, CIRM gave Asterias $14.3 million award, afterwards, BMR attorney Steve Blake filed multiple motions in court for court sanction, writ of execution, court-appointed receiver with malicious intention and primarily for improper purposes, such as harassment or intentionally cause needless increase in the cost of litigation that, BMR knew, a small stem cell startup in the life sciences industry could not afford, to force SDRMI handover its stem cell patent, hostile takeover, force SDRMI liquidate its asset into bankruptcy, compel SDRMI production of information and documents that contain information that is commercially sensitive, trade secret, proprietary, confidential and/or subject to a right of privacy entitled by law (please see BMR attorney’s frequent ex parte contacts with SDRMI and extortionate demand letters provided by BMR themselves below).

In the civil trial in San Diego Central Court for BMR alleged destruction of entire human embryonic stem cell stock and stem cell research facility of SDRMI (case#37-2013-00038680 and related case#37-2012-00042147 and case#37-2014-00034661, and court records can be viewed at http://www.sdcourt.ca.gov), the Judge allowed BMR outrageous cross-complaint and enter of faulty judgment of allegedly loss or damage that is caused by BMR own malicious conducts, that were never consented, nor remotely caused by SDRMI, and that was after BMR deliberately locked SDRMI out and accused SDRMI trespassing, including overcharged rents, fees, utilities, late fees, attorney fees, contract fees with OSI to destroy SDRMI stem cells and research materials, which BMR has greedily inflated each costs of their own malicious conducts to >200%, and bully alter ego doctrine to go after SDRMI’s founder Dr. Parsons, despite the facts that BMR’s allegation for loss or damage is not actual cost, unreasonable, without any receipts or proof, without SDRMI consent or any verification; BMR signed the lease with SDRMI using a non-existing entity – BMR 3030 Bunker Hill Street LLC (please see image files below); the applicable statute of limitation of the lease has expired; the lease was fraudulent, unenforceable, against public policy; SDRMI has suffered actual damages from BMR due to the fraudulence of the lease; BMR did not state sufficient facts to constitute a cause of the cross-complaint under any legal theory; the damages claimed by BMR, if any, was caused by BMR’s own conducts, not directly or proximately caused by SDRMI; the damages claimed by BMR is barred by the doctrine of laches; BMR has prejudiced SDRMI by its unlawful detainer action and other wrongful conducts; BMR has repeatedly and deliberately broke the contract, including multiple unauthorized entries, overcharged SDRMI utility by averaging the building utility against the lease, changed locks and inactivated access keys, failed to serve SDRMI notice properly, broke SDRMI freezer locks, damaged and destroyed SDRMI property, sold SDRMI property to their partner San Diego State University (SDSU) or donate to their partner Sustainable Surplus Exchange for sell (please see image files provided by BMR themselves through case discovery); BMR continued to send SDRMI rent statements for late payment according to the lease provision about the late payment, therefore, failed to make out a Prima Facie case that SDRMI broke the contract. The Judge allowed BMR entered the faulty judgment and verdict that are missing some crucial deliberations for BMR’s malicious intention and despicable conducts in destruction of entire human embryonic stem cell stock and stem cell research facility of SDRMI, and that is different from the original verdict handed to the Judge, which was not just two sentences for the verdict of BMR’s malicious intention and despicable conducts in destruction of entire human embryonic stem cell stock and stem cell research facility of SDRMI (please see image files provided by BMR themselves below). And even in the omitted or faulty verdict, the jury could not deny SDRMI’s ownership for its stem cell assets that were illegally confiscated, destroyed, and sold by BMR; and according to California civil code procedures, even if property is deemed abandoned, landlord BMR still has the duty to return it to its owner SDRMI, which BMR are subject to negligence and conversion for BMR’s conducts (please see image files provided by BMR themselves below). How come those crucial parts of jury deliberations in the verdict for BMR’s malicious intention and despicable conducts in destruction of entire human embryonic stem cell stock and stem cell research facility of SDRMI are missing or deliberately omitted? Why would BMR attorney Steve Blake demand for jury trials if he was not assured by BMR that BMR’s power and money would have a undisclosed way to tamper the jury trials and protect him from any wrong doings of malicious prosecutions (please see case#37-2013-00038680 and related case#37-2012-00042147 and case#37-2014-00034661, and court records can be viewed at http://www.sdcourt.ca.gov).

According to the unlawful detainer law, BMR has to obtain SDRMI’s agreement for sell or donate SDRMI’s stem cell research equipment. BMR had no rights to sign the donor agreement with Sustainable Surplus Exchange and sell SDRMI stem cell research equipment to San Diego State University (SDSU) since BMR did not have ownership for all the items listed, nor obtained any agreement from SDRMI. This information through case discovery uncovers a black market operation where BMR illegally confiscates valuable research equipment and materials of life science organization or company through fraudulent lease, false statements and wrongful accusations, then either destroys or sells in their partner organizations for profit. BMR fraudulent lease contained exit survey and provisions for the purpose of cleaning the premise only, it is despicable, unconscionable, illegal, contrary to public policy for BMR to abuse it as their rights or safe-harbor for their wrongdoings in confiscation, destruction, sell, and extortionate demand of SDRMI human embryonic stem cell assets and patent that BMR has neither ownership nor any rights. BMR’s black market operation has escalated into extortion for SDRMI’s patent rights using the money judgment and faulty verdict that BMR illegally obtained from the court using malicious persecutions to burden small life sciences with the costs of multiple legal defenses SDRMI could not afford (please see BMR attorney Steve Blake’s extortionate demand letters provided by BMR themselves below). Why would a commercial real estate company be interested in taking control of SDRMI’s stem cell asset and stem cell patent if there is no financial conflict of interest?


BMR provided the supporting documents below.






















Friday, October 24, 2014

Dr. Xuejun Parsons, the founder of Xcelthera Inc and San Diego Regenerative Medicine Institute, is going to speak at Cell Therapy 2014 Las Vegas on Current State of Regenerative Medicine -- Moving Stem Cell Research from Animals into Humans for Clinical Trials

Title: Direct Conversion of Pluripotent Human Embryonic Stem Cells into Functional Human Neuronal or Cardiomyocyte Cell Therapy Derivatives for Regenerative Medicine

Abstract: Given the limited capacity of CNS and heart for self-repair/renewal, cell-based therapy represents a promising therapeutic approach closest to provide a cure to restore normal tissue and function for neurological and cardiovascular disorders. Derivation of human embryonic stem cell (hESCs) from the in vitro fertilization (IVF) leftover embryos has brought a new era of cellular medicine for the damaged CNS and heart. Recent advances and technology breakthroughs in hESC research have overcome some major obstacles in moving stem cell research from animals towards humans trials, including resolving minimal essential human requirements for de novo derivation and long-term maintenance of clinically-suitable stable hESC lines and direct conversion of such pluripotent hESCs into a large supply of clinical-grade functional human neuronal or cardiomyocyte cell therapy products. Such breakthrough stem cell technologies have demonstrated the direct pharmacologic utility and capacity of hESC cell therapy derivatives for human CNS and myocardium regeneration and, thus, have presented the hESC cell therapy derivatives as a powerful pharmacologic agent of cellular entity for CNS and heart repair. The availability of human stem/progenitor/precursor cells in high quality and large commercial scales with adequate cellular neurogenic or cardiogenic capacity will greatly facilitate developing safe and effective cell-based regenerative therapies against a wide range of CNS and heart disorders. Transforming non-functional pluripotent hESCs into fate-restricted functional human cell therapy derivatives dramatically increases the clinical efficacy of graft-dependent repair and safety of hESC-derived cellular products, marking a turning point in cell-based regenerative medicine from current studies in animals towards human trials.

Time and Location: Wednesday, October 29, 2014 at Embassy Suites, Las Vegas, 4315 Swenson Street, Las Vegas, Nevada 89119, USA


Wednesday, October 22, 2014

Biomed Realty Trust Inc (BMR), a Public Company that has Failed to Disclose its Legal Proceedings to SEC and the Public against SEC Regulations and Public Policy, is Making False Accusations, Alleging Defamation Lawsuit, and Threatening Restraining Order and Injunction to Bully Human Embryonic Stem Cell Research Blog and Private Sectors for Speaking Truth about BMR’s Deliberate Destruction to Human Embryonic Stem Cells and Damages to Private Life Science Startup – What BMR Has to Hide?

All the information disclosed below is privileged and provided by BMR, SDRMI, and other sources through case discovery. This blog makes no representations as to accuracy, completeness, correctness, reliability, suitability, or validity of this information. The content on this blog is the opinion only, not intended to malign any religion, ethnic group, club, organization, company, or individual, or anyone or anything.

BioMed Realty Trust Inc (BMR), a public traded company advertising itself as the world largest commercial real estate specializing in leasing laboratory spaces to life science industry, has failed to disclose its legal proceedings to the United States Security and Exchange Commission (SEC) and the Public in consecutive quarterly reports against SEC regulations and Public Policy (please see http://www.sec.gov/ and image files of BMR SEC reports below). BMR’s board members include trustees and president of Salk Institute; trustee of Stanford University; CEO of Amylin Pharmaceuticals; boards of directors of Illumina, Geron Corporation, Alliance Pharmaceutical Corp, Corcept Therapeutics, and Castle Biosciences; the advisory councils of the University of California San Diego and the University of Miami; President of Roth Capital (please see http://www.biomed.com ). BMR’s biotechnology company investment portfolio includes some of the trailblazers in human embryonic stem cell lines, such as Geron and Asterias Biotherapeutics, a subsidiary of Biotime, which dosed on stem cell assets of Geron in October 2013 under a ~ $40 million deal for acquiring four cell lines, including OPC1, that were shelved by Geron. Asterias entered into an 8-year lease contract with BMR in January 2014 that worth ~$1.5 million/year, and subsequently, received a $14.3 million award from California Institute for Regenerative Medicine (CIRM) in May 2014 to continue clinical trial of OPC1 for spinal cord injury abandoned by Geron in November 2011.

BMR, a public-traded company, has been a party of multiple legal proceedings including case#37-2013-00038680 and case#37-2012-00042147 (court records can be viewed at http://www.sdcourt.ca.gov), which disclosed through case discoveries BMR’s shocking malicious intention and despicable conducts in illegal confiscation and destruction of valuable human embryonic stem cell lines and stem cell research materials of San Diego Regenerative Medicine Institute (SDRMI) – a privately-hold stem cell startup in life science industry, and illegal confiscation and sell of stem cell research equipment of SDRMI with its partner organizations through fraudulent lease against public policy, invalid legal documents, false statements in legal documents under the penalty of perjury under the laws of the State of California, default and judgment that contain multiple legal deficiencies, and failure to follow proper legal procedures. However, BMR has reported to SEC repeatedly during last consecutive quarters that BMR is not currently a party to any legal proceedings nor is any legal proceeding threatened against BMR that BMR believe would have a material adverse effect on its financial position, results of operations or liquidity against SEC regulations (please see http://www.sec.gov/ and image files of BMR SEC reports below). To cover up that BMR has violated public policy and government regulations to deliberately withhold information about its legal proceedings and multiple legal deficiencies to SEC and the Public, BMR is making false accusations and alleging defamation lawsuit (Case#37-2014-00034661, court records can be viewed at http://www.sdcourt.ca.gov, please see image files provided by BMR themselves below), threatening restraining order and injunctions to bully Voice of Regenerative Medicine – a human embryonic stem cell research blog – and extort private sector unrelated individuals and startups for speaking truth about BMR’s legal proceedings that contain multiple legal deficiencies; violates the legal rights, ownership, and privacy of US private organizations and citizens, including US veteran and POW, entitled by law; and resulted in deliberate destruction to human embryonic stem cells of SDRMI and devastating damages to private life science startup (case#37-2013-00038680, case#37-2012-00042147, and case#37-2014-00034661, court records can be viewed at http://www.sdcourt.ca.gov, please see image files and BMR attorney’s frequent ex parte contacts and extortionate demand letters provided by BMR themselves below). What BMR, a public company that has failed to disclose its legal proceedings to SEC against public policy and government regulations, has to hide from SEC, the public, and the share holders?


BMR provided the supporting documents below.